DRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alpha Tau Medical Ltd (DRTS) is not a strong buy for a beginner, long-term investor at this time. The stock lacks significant positive momentum, financial growth, or clear trading signals. While there are some positive catalysts, such as Japan's approval of Alpha DaRT and analyst optimism, the company's financials and commercialization timeline do not align with the user's impatience and preference for immediate investment opportunities.
The MACD is negatively expanding, RSI is neutral at 37.001, and moving averages are converging, indicating no clear bullish trend. The stock is trading near its support level of 6.882, with resistance levels at 7.569 and 7.782. Overall, the technical indicators suggest a lack of strong upward momentum.
Japan's approval of Alpha DaRT for head and neck cancer, which validates the platform and de-risks U.S. clinical development. Analysts from Citi and H.C. Wainwright have raised price targets and maintained Buy ratings, citing the company's underappreciated value and potential.
Piper Sandler downgraded the stock to Neutral, citing valuation concerns and the lack of near-term revenue realization. The path to full commercialization of Alpha DaRT technology is still 2-3 years away. No recent news or significant trading activity from hedge funds, insiders, or Congress.
In Q4 2025, the company reported no revenue growth (0% YoY), a net loss of $12.14 million (improved by 28.07% YoY), and an EPS of -0.14. Gross margin remains at 0%. The financials show no immediate growth trajectory.
Analyst sentiment is mixed. Citi and H.C. Wainwright are bullish, raising price targets to $9 and $12, respectively, while Piper Sandler downgraded the stock to Neutral with a $5 price target, citing valuation concerns and the need for revenue realization.
